source
- Pfizer halts phase 2 trial of CXCR5 antibody for immune thrombocytopeniaPfizer announced it is ending a phase 2 study of its CXCR5-targeting antibody PF-06835375 in patients with primary immune thrombocytopenia (ITP). The decision was described as a business decision a…
- AstraZeneca partners with Oracle to boost clinical trial patient recruitment using AIAstraZeneca announced a collaboration with data-technology firm Oracle to apply artificial-intelligence tools to clinical-trial recruitment. The non-binding agreement will let the partners explore…